In an epidemiological investigation, SGLT inhibitors improved atherosclerosis and reduce the risk of cardiovascular and cerebrovascular events.[60] The Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) study results were presented at the 66th Annual Meeting of the American College of Cardiology. The gene discussed is SLC5A2; the disease is atherosclerosis.